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EDITORIAL
Nodular parathyroid growth: Role of vitamin D resistance
The parathyroid gland is a low turnover, discontinu- growth [6]. Similar to parathyroid adenomas in humans,
ously replicating tissue composed of cells that rarely un- these mice slowly develop large hyperplastic glands and
dergo mitoses [1, 2]. The quiescent parathyroid cells, in some cases adenomatous glands. However, in nodular
however, retain their potential to divide in response to hyperplasia in humans, different from parathyroid ade-
growth stimuli, including the onset of renal failure, low nomas, no correlation exists between levels of cyclin D1
calcium, high phosphorus, or vitamin D deficiency [2]. and mitogenic activity. More important, these studies in
In patients with renal failure, parathyroid glands initially mice [6] and recent studies in uremic rats [7] also indi-
grow diffusely and polyclonally. In advanced stages of cated that reduced CaSR in the parathyroid glands fol-
parathyroid hyperplasia, the cells in the nodules trans- lowed rather than caused the hyperplasia.
form monoclonally and proliferate aggressively [3]. Nod- Studies by Tokumoto et al [8], in this issue of Kidney
ular hyperplasia constitutes the more severe form of International, present the impaired induction of the ex-
secondary hyperparathyroidism. Neither the mecha- pression of the cyclin-dependent kinase inhibitors p21
nisms triggering the initial increase in proliferating activ- and p27 by the VDR as a pathogenic mechanism for
ity nor those resulting in changes in growth pattern are nodular parathyroid growth in renal failure. Examina-
completely elucidated. tion of nodular hyperplastic parathyroid tissue from 23
Recent studies in 5/6 nephrectomized rats have impli- patients demonstrated a strong direct correlation be-
cated elevations of transforming growth factor-alpha tween VDR levels and parathyroid content of the cyclin-
(TGF-) expression in the increased proliferating activ- dependent kinase inhibitors p21 and p27. More impor-
ity of parathyroid cells in early renal failure [4]. High tant, the lower the parathyroid levels of VDR and cyclin-
dietary phosphorus intake further enhances parathyroid dependent kinase inhibitors, the higher the markers of
levels of TGF- and therefore, proliferation rates [4]. proliferating activity and the size of the nodular gland.
Prevention of the increases in TGF- and induction of The lack of an association between parathyroid levels
parathyroid levels of the cyclin-dependent kinase inhibi- of p21 and p53, the main regulator of p21 expression,
tor p21 by high dietary calcium, phosphorus restriction, suggested a direct induction of p21 by the VDR as a
or vitamin D therapy mediate their effects in attenuating potential mechanism. The lack of a parathyroid cell line
or completely counteracting the growth-promoting sig- and the diffuse pattern of parathyroid hyperplasia in
nals triggered by uremia [4, 5]. The relative contribution uremic rats, however, prevent from conclusive validation
of either mechanism to arrest parathyroid growth re- of the proposed model, which emerges solely from simul-
mains unclear. taneous assessment of parathyroid expression of VDR
High calcium and vitamin D are efficient in controlling and cell-cycle regulators in nodular human parathyroid
parathyroid levels of TGF- and its downstream-growth glands. Nevertheless, the findings by Tokumoto et al
signal, cyclin D1, in an experimental model of early ure- further our understanding on the pathogenesis of the
mia [5]. This finding suggests a role for the progressive abnormalities in parathyroid cell replication that could
reduction in the levels of the calcium-sensing receptor help improve therapeutic strategies to avoid the more
(CaSR) and the vitamin D receptor (VDR) in the wors- severe form of secondary hyperparathyroidism. Their
ening of proliferating activity in patients with advanced results support the findings from studies in early uremia
renal failure. In fact, higher cyclin D1 expression occurs in rats on the importance of vitamin D induction of
in nodular hyperplasia compared to diffuse hyperplastic parathyroid p21 expression in regulating the rate of para-
glands [3]. However, neither the increase in cyclin D1 thyroid cell proliferation [5]. In addition to confirming
expression nor the reduction in CaSR is a key determi- the association between a reduction in p27 and hyper-
nant of the switch to the more aggressive nodular growth. plastic growth in secondary hyperparathyroidism [9],
Studies in transgenic mice targeted to specifically overex- their demonstration of vitamin D-dependent regulation
press cyclin D1 in the parathyroids conclusively demon- of p27 in the parathyroids suggests an additional mecha-
strated the importance of cyclin D1 in parathyroid nism for the resistance to the antiproliferative effects of
the sterol in nodular hyperplasia. In aggressive carcino-
mas, where growth is driven exclusively by TGF- activa-Key words: TGF-, hyperplasia, cyclin-dependent kinase inhibitors,
p21, p27, uremia, calcium-sensing receptor, vitamin D receptor tion of signaling by its receptor, the epidermal growth
factor receptor (EGFR), increases in p27 are mandatory 2002 by the International Society of Nephrology
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